Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Neodent® Zirconia System Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04545840
Recruitment Status : Active, not recruiting
First Posted : September 11, 2020
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Neodent

Brief Summary:

The Neodent® Zirconia Implant is designed for the treatment of oral endosteal implantation for the functional and aesthetic rehabilitation, allowing for treatment of patients with different bone qualities.

The objective of the study is to assess the success and survival rates of implantable devices of the Zirconia System, in order to confirm the long-term safety and clinical performance of implants and abutments of the Zirconia System in daily dental practice setting.

Devices will be used according to standard routine in daily practice, according to manufacturer indications in the IFU. Patients will be followed for 36 months after implant placement.


Condition or disease Intervention/treatment
Jaw, Edentulous Jaw, Edentulous, Partially Device: Dental Implants

Detailed Description:

The study protocol was reviewed and approved by an Ethics Committee (CE) in Brazil. The sample will be prospectively and consecutively selected and will consist of patients who are 18 years of age or older, who are in need of and who qualify for single dental implants placement in the posterior maxilla region with Neodent® Zirconia. Informed consent in writing will be obtained from each patient participating in the study prior to any study related procedure.

As this study will be analyzed descriptively, sample size calculation was not performed. To generate reliable results, a total number of 30 implants was assumed to be sufficient. Estimating a rate of 1 implant per patient and a drop-out rate of 15%, a sample size of 36 patients resulting in an estimated number of 36 implants is thought to be sufficient to allow for a descriptive analysis of clinical outcome data up to 36 months after implant placement.

Treatment provided to the subjects will be the responsibility of an appropriately qualified dental practitioner to provide the relevant patient care under clinical study conditions. Zirconia Implants will be placed under local anesthesia and with adequate bone bed preparation in posterior maxilla region. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.

Immediately after implant placement, the final placement torque will be registered. The immediate loading will be applied within 48 hours with the insertion of a provisional prosthesis made from intraoral scanning or scanning of dental casts obtained by conventional impression. The insertion torque shall reach at least 35 N.cm and the subject must have physiologic occlusion to immediate loading. If the patient does not reach the minimum torque (35 N.cm), the patient will be followed until the study end but will not be considered to final statistic or, a different implant line would be placed and the study termination form will be filled. The principal investigator will choose how to procedure in this situation. The selection of the prosthetic component shall be conducted according to the need of each subject and to the manufacturer's instructions (IFU). The final prosthesis will be placed 2 months after implant loading.

Data concerning the studied variables will be collected following the procedures and assessments plan by fulfilling the Case Report Form (CRF), in the following stages: screening (First visit); TP - Implant(s) placement and impression/scanning for temporary prosthesis preparation; T0 - Implant(s) loading (up to 48h after placement); TF - Final prosthesis placement (2 months ± 1 week after loading); T6, T12, T24, T36 - 6, 12, 24 e 36 ± 1 month, respectively, after loading.

Standardized digital periapical radiographs will be obtained in a usual daily practice frequency, as determined by the investigator: at pre-operative, to assess the ridge height and width of the supporting bone and locate major anatomical features; in post-surgery (TP) and in T0, TF, T6, T12, T24 and T36 to verify prosthesis adaptation and osseointegration. Computed tomography scans will be obtained from the region of interest prior to surgery, for the selection of the implant to be inserted.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 36 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Study of Neodent® Implantable Devices of Zirconia System
Actual Study Start Date : September 10, 2020
Estimated Primary Completion Date : April 30, 2023
Estimated Study Completion Date : April 30, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Zirconium

Group/Cohort Intervention/treatment
Study group
Zirconia Implants will be placed. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.
Device: Dental Implants
Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).




Primary Outcome Measures :
  1. Implant survival rate [ Time Frame: 36 months after implant placement ]
    Implant survival will be defined as no loss of the implant.

  2. Implant success rate [ Time Frame: 36 months after implant placement ]
    Evaluation of implant success will be assessed based on the criteria proposed by Buser et al. (1990).


Secondary Outcome Measures :
  1. Implant survival rate [ Time Frame: 6 months after implant placement ]
    Implant survival will be defined as no loss of the implant.

  2. Implant success rate [ Time Frame: 6 months after implant placement ]
    Evaluation of implant success will be assessed based on the criteria proposed by Buser et al. (1990).

  3. Prosthetic survival rate [ Time Frame: 36 months after implant placement ]
    Prosthetic survival will be assessed as the final prosthesis remaining in situ, irrespective of its condition.

  4. Prosthetic success rate [ Time Frame: 36 months after implant placement ]
    Success will be defined as the prosthesis that remained unchanged and did not require any intervention, except routine occlusal adjustments, during the entire observational period

  5. Patient satisfaction: questionnaire [ Time Frame: At screening visit, after the temporary prosthesis period and 6, 12, 24 and 36 months after implant placement ]
    OHIP-14 questionnaire will be used to assess Oral Health Related Quality of Life (OHRQoL), as a measure of patient satisfaction with treatment. Patients will be asked how frequently they have been experiencing the problems assessed by the questionnaire. Small values mean a better quality of life.

  6. Clinician satisfaction: questionnaire [ Time Frame: At implant placement, implant loading and 6, 12, 24 and 36 months after implant placement ]
    The assessment will be performed by means of a questionnaire using a visual analog scale (VAS) in the form of a 10 cm horizontal line, where 0 (left end) indicates minimum satisfaction and 10 (right end) indicates maximum satisfaction. The clinician will be instructed to mark the position considered to best represent their degree of general satisfaction with patient treatment. The score will be measured in centimeters from the left end of the line to the marked point.

  7. Rate of adverse events related to the implant, prosthesis, surgery and oral health [ Time Frame: At implant placement, implant loading, final prosthesis placement and 6, 12, 24 and 36 months after implant placement ]
    Determined by inquiring with the patient and clinical evaluation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients 18 years of age or older who are in need of and who qualify for single dental implants placement in the posterior maxilla region with Neodent® Zirconia Implants.

Patients that give written informed consent to participate in this clinical study.

Criteria

Inclusion Criteria:

  • 18 years of age or older;
  • Maxillary posterior teeth missing, with adjacent natural teeth;
  • Patient who are in need of oral rehabilitation with dental implants and single prostheses and qualify for placement of Zirconia Implants.

Exclusion Criteria:

Subjects under 18 years of age, pregnant or breastfeeding women. And patients that present the device contraindications according to the IFU (instructions for use):

  • Signs of allergy or hypersensitivity to the chemical ingredients of the material: Zirconia (Y-ZTP), Zirconium dioxide (ZrO2), Yttrium oxide (Y2O3), Hafnium dioxide (HfO2), Aluminum oxide (Al2O3);
  • Acute inflammatory or infectious processes;
  • Unsuitable bone volume or quality;
  • Serious medical problems (e.g. bone metabolism disorders, blood clotting disorders, unsuitable healing capacity);
  • Incomplete jawbone growth;
  • Patient uncooperative and not motivated;
  • Hypochondria;
  • Alcoholism;
  • Psychosis;
  • Prolonged functional disorders which resist any treatment with medications;
  • Xerostomia;
  • Weakened immunological system;
  • Diseases which require regular use of steroids;
  • Uncontrolled endocrine diseases;
  • Insufficient oral hygiene;
  • Pregnancy;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04545840


Locations
Layout table for location information
Brazil
Instituto Latino Americano de Pesquisa e Ensino Odontológico (ILAPEO)
Curitiba, Paraná, Brazil, 80710-150
Sponsors and Collaborators
Neodent
Investigators
Layout table for investigator information
Study Chair: Larissa Trojan, PhD Neodent
Layout table for additonal information
Responsible Party: Neodent
ClinicalTrials.gov Identifier: NCT04545840    
Other Study ID Numbers: CS.O.010
First Posted: September 11, 2020    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Neodent:
Dental Implants
Mouth Rehabilitation
Additional relevant MeSH terms:
Layout table for MeSH terms
Jaw, Edentulous
Jaw, Edentulous, Partially
Mouth, Edentulous
Mouth Diseases
Stomatognathic Diseases
Tooth Diseases
Jaw Diseases
Musculoskeletal Diseases